Gilead Sciences

US · GILD #83 by market cap Listed 1992 Quant Rating C 63

151.00 -0.23 -0.15%

Collector offline (last heartbeat: 19009s ago) · 2026-09-04 20:02

Pre-market 149.28 -1.28%

After-hours 151.00 0.00%

Overnight 150.73 -0.32%

Market cap: 187.23B
P/E (TTM): -56.98
P/B: 15.83
EPS: 6.78
Div yield: 2.13%
52W pos: 91%

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company focused on HIV, liver disease, hematology, oncology, and inflammatory and respiratory conditions, selling antiviral treatments under brands including Harvoni, Biktarvy-era successors to Truvada and Atripla, and Sovaldi. Michael Riordan founded the company on June 22, 1987; it is headquartered in Foster City, California.

Founded: 1987
CEO: Mr. Daniel P. O'Day
Employees: 17,000
Headquarters: Foster City, California, United States of America
Fiscal year end: 12-31
Website: gilead.com

View SEC filings on EDGAR ›

Company profile

Exchange: US
Symbol: GILD
Market-cap rank: #83
Listing date: 1992-01-24
Market cap: 187.23B
Float cap: 186.82B
Shares out: 1.24B
Float shares: 1.24B

Sectors & themes

Drug Manufacturers - General CAR-T Therapy Infectious Disease Cancer Research Mpox (monkeypox) Global medical industry Regular Savings Plan Fractional Shares JP

Browse all sectors & themes

Quote time 2026-09-04 20:02:21

For reference only, not investment advice.